エクソソーム療法市場：治療薬タイプ別（同種および自家）、適応症別（変性半月板損傷、肥厚性表皮水疱症、肛門周囲瘻、網膜色素変性症）、治療領域別（皮膚疾患、治療領域（皮膚疾患、筋骨格系疾患、眼科疾患、直腸疾患）、投与経路（瘻管、関節内、眼内）、地域（北米、欧州、アジア太平洋地域、その他の地域）：産業動向と世界予測、2022-2040年

Exosome Therapy Market, Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2040

医療・製薬業界におけるエクソソーム療法市場は、2022年には3,200万米ドルに達し、予測期間2023-2040年には年平均成長率41.2％で成長すると予測されている。近年、細胞外小胞に基づく治療法は医療分野で大き... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年1月1日	US$4,799 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	190	英語

サマリー

医療・製薬業界におけるエクソソーム療法市場は、2022年には3,200万米ドルに達し、予測期間2023-2040年には年平均成長率41.2％で成長すると予測されている。

近年、細胞外小胞に基づく治療法は医療分野で大きな支持を得ており、さまざまな病状への応用が期待されることから、業界関係者から大きな注目を集めています。この関心の高まりは主に、その正確な標的化能力、組織再生の促進、炎症や慢性疼痛を緩和する可能性から生じている。膜結合型細胞外小胞の一種であるエクソソームは、その多様な利点から特に注目されており、疾病診断、薬物送達、治療介入にわたる広範な研究につながっている。このような研究の高まりは、エクソソームに基づく治療薬の開発に産業界と非産業界の両方が取り組むことを促し、一部は臨床試験を経て進展している。さらに、COVID-19のパンデミックは、エクソソーム治療の探求を著しく加速させ、COVID-19の複雑性と関連合併症を標的とした治験薬（IND）申請の増加で明らかである。

間葉系幹細胞（MSC）由来のエクソソームを前臨床で評価した200以上の研究を網羅した最近の包括的レビューによると、これらのエクソソームは実施された研究の70％以上で良好な結果を示した。このことは、多様な治療法におけるMSC由来エクソソームの有効性と可能性を立証し、医療介入の進歩におけるエクソソームの重要性をさらに浮き彫りにしている。

レポート範囲
 エクソソーム治療市場に焦点を当て、治療の種類、標的適応症、治療領域、投与経路、地理的分布を考慮した分析。
 市場成長に影響を与える促進要因、阻害要因、機会、課題を含む要因の検討を行います。
 主要市場プレイヤー間の競争環境に関する洞察とともに、市場環境における潜在的な利点と障壁を評価します。
 市場セグメントの収益予測を4つの主要地域で予測しています。
 エクソソームについて、様々なタイプの細胞外小胞、その起源、分泌、膜組成、発生プロセス、治療への応用を包含して詳細に解説。エクソソーム治療の利点、リスク、将来展望についての考察も含まれる。
 開発段階、技術プラットフォーム、ペイロードの種類、対象疾患、治療領域、生物学的標的、投与経路、治療タイプ、関連企業、設立年、規模、本社に基づく評価。
 主要なエクソソーム治療企業の包括的なプロファイルを掲載し、パイプライン、財務データ、製品ポートフォリオ、最近の開発状況、将来の展望に焦点を当てています。
 製品ポートフォリオ、臨床試験の詳細、フェーズ、場所、患者登録、試験期間を網羅した、開発段階の主要エクソソーム療法の詳細情報。
 エキソソーム治療薬に関連する完了済みおよび進行中の臨床試験を、試験状況、登録年、スポンサー、試験デザイン、患者登録、傾向、参加者属性、試験場所に基づいて検討。
 2017-2022年にエクソソーム治療プロジェクトのために研究機関に授与された助成金を、資金提供の詳細、助成金の目的、受領組織、新たな重点分野に焦点を当てて詳細に分析。
 エキソソーム治療開発者が参加したイベントの分析。イベントの詳細、開催地、参加者の属性、積極的な主催者、業界の関与、参加者の指定、講演者を網羅。
 2017年以降に設立されたパートナーシップの検討、エクソソーム療法業界における研究契約、ライセンス供与、製造、開発/商業化取引、合併/買収を網羅。
 2017年以降にエクソソーム治療企業に行われた投資の分析（助成金、資金調達の種類、IPO、オファリング、負債性資金調達、株式、資金調達の詳細を含む）。
 エクソソーム治療薬に携わる新興企業を、パイプラインの強さ、成熟度、財務的裏付け、投資家数、提携、新興企業の健康指標に基づいて評価。
 エクソソームの開発・製造サービスを提供する企業のケーススタディ。サービスの種類、分離、特性評価、精製方法、製造プロセス、拡張性、事業規模を網羅。
 後期臨床段階に進めなかったエクソソーム治療薬について、中止状況、対象疾患、投与経路、スポンサータイプに基づいて検討。

主要市場企業
 Coya Therapeutics
 Evox Therapeutics
 Curexsys
 EV セラピューティクス
 SHIFTBIO

ページTOPに戻る

1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapy
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics
4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment
4.3. Exosome Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
5. EXOSOME THERAPY : COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook
5.2. Evox Therapeutics
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. SHIFTBIO
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
6. EXOSOME THERAPY: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status
7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography
8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships
10.3.13. Distribution by Geography
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity
12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups
13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Companies Landscape
13.2.1. Analysis by Year of Establishment
13.2.2. Analysis by Company Size
13.2.3. Analysis by Location of Headquarters
13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Scalability
14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapy Market, 2029-2040
15.2.1. Exosome Therapy Market for Allogeneic Therapy, 2029-2040 (USD Million)
15.2.2. Exosome Therapy Market for Autologous Therapy, 2029-2040 (USD Million)
15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapy Market for Fistula Perianal, 2029-2040 (USD Million)
15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapy Market for Ophthalmic Disorders, 2029-2040 (USD Million)
15.2.10. Exosome Therapy Market for Rectal Disorders, 2029-2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapy Market, 2029-2040 (USD Million)
15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapy Market, 2029-2040 (USD Million)
15.2.14. Exosome Therapy Market Geographical Distribution, 2029-2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)
16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Soonho Song, Chief Business Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

Table of Contents

Summary

The exosome therapy market in healthcare and pharmaceutical industry is expected to reach USD 32 million in 2022 and anticipated to grow at a CAGR of 41.2% during the forecast period 2023-2040.

In recent years, extracellular vesicle-based therapies have gained significant traction in the medical field, attracting considerable attention from industry stakeholders due to their promising applications across various medical conditions. This heightened interest primarily arises from their precise targeting capabilities, facilitation of tissue regeneration, and their potential to alleviate inflammation and chronic pain. Exosomes, a specific type of membrane-bound extracellular vesicles, have particularly garnered attention due to their manifold advantages, leading to extensive research across disease diagnosis, drug delivery, and therapeutic interventions. This growing body of research has prompted both industry and non-industry entities to delve into developing exosome-based therapeutics, with some progressing through clinical trials. Moreover, the COVID-19 pandemic has notably accelerated the exploration of exosome therapy, evident in the increased submissions of investigational new drug (IND) applications targeting COVID-19 complexities and associated complications.

A recent comprehensive review encompassing over 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use revealed that these exosomes demonstrated favorable outcomes in more than 70% of the conducted studies. This substantiates the efficacy and potential of MSC-derived exosomes across diverse therapeutic modalities, further highlighting their importance in advancing medical interventions.

Report Coverage
 The analysis focuses on the exosome therapy market, considering the types of therapy, target indications, therapeutic areas, route of administration, and geographical distribution.
 Examination of factors, including drivers, restraints, opportunities, and challenges, impacting market growth is conducted within the report.
 Evaluation of potential advantages and barriers within the market landscape is provided, along with insights into the competitive environment among key market players.
 Revenue forecasts for market segments are projected across four major regions.
 Detailed explanation of exosomes, encompassing various extracellular vesicle types, their origin, secretion, membrane composition, developmental process, and therapeutic applications. Included are discussions on advantages, risks associated with exosome therapy, and future prospects.
 Assessment based on development phases, technology platforms, payload types, target disease indications, therapeutic areas, biological targets, administration routes, therapy types, companies involved, establishment year, size, and headquarters.
 Comprehensive profiles of major exosome therapy companies, focusing on their pipeline, financial data, product portfolio, recent developments, and future outlook.
 Detailed information on leading exosome therapies in advanced development phases, covering product portfolio, clinical trial details, phase, locations, patient enrollment, and trial duration.
 Examination of completed and ongoing clinical trials related to exosome therapeutics, based on trial status, registration year, sponsors, study designs, patient enrollment, trends, participant demographics, and trial locations.
 In-depth analysis of grants awarded to research institutes for exosome therapeutic projects from 2017-2022, focusing on funding details, grant purposes, recipient organizations, and emerging focus areas.
 Analysis of events attended by exosome therapy developers, encompassing event details, locations, participant demographics, active organizers, industry involvement, participant designations, and speakers.
 Examination of partnerships established since 2017, covering research agreements, licensing, manufacturing, development/commercialization deals, mergers/acquisitions in the exosome therapy industry.
 Analysis of investments made in exosome therapeutic companies since 2017, including grants, financing types, IPOs, offerings, debt financing, equity, and funding details.
 Evaluation of start-ups engaged in exosome therapeutics based on pipeline strength, maturity, financial backing, investor count, partnerships, and start-up health indexing.
 A case study on companies offering exosome development and manufacturing services, covering service types, isolation, characterization, purification methods, manufacturing processes, scalability, and scale of operation.
 Examination of exosome therapeutics that did not progress to later clinical stages, based on discontinuation status, target diseases, administration routes, and sponsorship type.

Key Market Companies
 Coya Therapeutics
 Evox Therapeutics
 Curexsys
 EV Therapeutics
 SHIFTBIO

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?